Authors :
Srishti Deshpande; Neha Rangwar; Aashutosh Sinwal; Ishu; Pooja Brahambhatt; Aman Saini
Volume/Issue :
Volume 9 - 2024, Issue 2 - February
Google Scholar :
https://tinyurl.com/muxr4za9
Scribd :
https://tinyurl.com/mr3zhb44
DOI :
https://doi.org/10.38124/ijisrt/IJISRT24FEB1599
Abstract :
Dermatomyositis (DM) is an idiopathic
inflammatory myopathy condition. It might be
challenging to identify DM when the usual dermatologic
symptoms or myopathy are not present. The onset of
muscle involvement is often pain or myalgias, however, it
can also be accompanied by proximal muscle weakening.
The incidence rate was estimated to be 9.63 per 1,000,000
inhabitants in Olmsted County, Minnesota, according to
a retrospective research that ran from 1967 to 2007. The
exact reason(s) behind dermatomyositis are still a
mystery. Environmental, immunological, and genetic
variables may all have an impact, though. Diabetic
myopathy (DM) is characterized by a progressive
weakening of muscles, which might start mild and
develop over a few weeks or months, or it can advance
more rapidly. Typically, symmetric and proximal muscle
involvement is the first to manifest, with distal muscle
weakening developing later in the disease's progression.
Muscle weakness, skin disease, and other underlying
problems are the main focuses of dermatomyositis
management. Systemic glucocorticoids, with or without
immunosuppressants, are the initial line of defense
against dermatomyositis-related muscle illness.
Management relies heavily on physical therapy and
rehabilitation. Active exercise programs should be
advocated for patients with moderate illness.
Keywords :
Dermatomyositis, Interstitial Lung Disease, Diabetes Mellitus, Immunosuppressants, Electromyography.
Dermatomyositis (DM) is an idiopathic
inflammatory myopathy condition. It might be
challenging to identify DM when the usual dermatologic
symptoms or myopathy are not present. The onset of
muscle involvement is often pain or myalgias, however, it
can also be accompanied by proximal muscle weakening.
The incidence rate was estimated to be 9.63 per 1,000,000
inhabitants in Olmsted County, Minnesota, according to
a retrospective research that ran from 1967 to 2007. The
exact reason(s) behind dermatomyositis are still a
mystery. Environmental, immunological, and genetic
variables may all have an impact, though. Diabetic
myopathy (DM) is characterized by a progressive
weakening of muscles, which might start mild and
develop over a few weeks or months, or it can advance
more rapidly. Typically, symmetric and proximal muscle
involvement is the first to manifest, with distal muscle
weakening developing later in the disease's progression.
Muscle weakness, skin disease, and other underlying
problems are the main focuses of dermatomyositis
management. Systemic glucocorticoids, with or without
immunosuppressants, are the initial line of defense
against dermatomyositis-related muscle illness.
Management relies heavily on physical therapy and
rehabilitation. Active exercise programs should be
advocated for patients with moderate illness.
Keywords :
Dermatomyositis, Interstitial Lung Disease, Diabetes Mellitus, Immunosuppressants, Electromyography.
